转换为卢拉西后延长的QTc间隔正常化:一个案例系列
Daisuke Takeuchi1, Naoto Omata1,2, Junichi Murayama1
1Department of Psychiatry, Fukui Hospital.
Journal of clinical psychopharmacology
|February 25, 2026
概括
切换到非典型抗精神病药物卢拉西,有效地减少了之前用其他精神病药物治疗的患者的QTc延长. 这表明,卢拉西可能会降低精神病患者突然心脏死亡的风险.
科学领域:
- 心脏病学 心脏病学
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- QTc延长是抗精神病药和抗抑郁药的严重副作用,可能导致致命的心律失常,如torsade de pointes.
- 卢拉西是一种非典型的抗精神病药物,其QTc延长的发生率很低.
- 在现有QTc延长的患者中,切换为卢拉西的影响尚未得到充分证实.
研究的目的:
- 为了研究转换为卢拉西对 QTc 间隔的影响,在因其他抗精神病药物或抗抑郁药物而导致 QTc 延长的患者中.
主要方法:
- 一个病例系列包括9名住院患者的QTc延长.
- 在转换为卢拉西之前和之后测量QTc间隔.
主要成果:
- 大多数患者在转换为卢拉西后显示QTc间隔的缩短.
- 这表明卢拉西在控制QTc延长方面具有潜在的益处.
结论:
- 转换为卢拉西可以有效地减少其他精神病药物诱导的QTc延长.
- 路拉西可以通过缩短QTc间隔来降低精神病患者突然心脏死亡的风险.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
Dysrhythmias IV: Characteristics of Bradyarrhythmias
664
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
664
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
3.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K
Dysrhythmias VI: Management of Dysrhythmias
544
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
544
Antiepileptic Drugs: Potassium Channel Activators
853
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
853
Dysrhythmias I: Introduction
689
Dysrhythmias refers to abnormalities in the heart's rhythm. They result from disruptions in the heart's electrical conduction system, which includes the sinoatrial(SA)node, atrioventricular(AV) node, the bundle of His, bundle branches, and Purkinje fibers.Definition and PathophysiologyDysrhythmias result from disorders of impulse formation, impulse conduction, or both. The heart contains specialized cells in the sinoatrial node, atrioventricular node, and the bundle of His and Purkinje fibers...
689


